Brodalumab (AMG827; KHK4827) is a fully human IgG2 mAb that works by blocking the IL-17RA chain of the IL-17 receptor on the cell surface compared to the first two antibodies, and is the first anti-IL-17RA inhibitor to treat psoriasis. Here, IL17RA is linked to psoriasis.